New drug could keep lung cancer from coming back after surgery

NCT ID NCT06931717

Recruiting now Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cemiplimab or be observed without treatment. The main goal is to see if the drug improves disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (a drug that helps the immune system fight cancer)
What this could lead to: If it works, this could offer a new option to delay or prevent lung cancer recurrence after surgery without needing chemotherapy.
What could go wrong: This is still being tested—results are not yet known. The drug may cause immune-related side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

AOU Maggiore della Carità
NOT_YET_RECRUITING

Novara, Italy
AULSS2 Marca Trevigiana Treviso
NOT_YET_RECRUITING

Treviso, Italy
Azienda Ospedaliera Universitaria Integrata di Verona
RECRUITING

Verona, Italy
Azienda ospedaliero-universitaria Senese Siena
NOT_YET_RECRUITING

Siena, Italy
Beaumont Hospital
RECRUITING

Dublin, Ireland
CHU d'Angers
NOT_YET_RECRUITING

Angers, France
Centre hospitalier d'Avignon
NOT_YET_RECRUITING

Avignon, France
Complejo Hospitalario Universitario
RECRUITING

A Coruña, Spain
Cork University Hospital
NOT_YET_RECRUITING

Cork, Ireland
Evangelische Lungenklinik Berlin
NOT_YET_RECRUITING

Buch, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
NOT_YET_RECRUITING

Milan, Italy
Fondazione IRCCS Policlinico S. Matteo
RECRUITING

Pavia, Italy
Hospital Clínico San Carlos
RECRUITING

Madrid, Spain
Hospital Clínico San Cecilio de Granada
RECRUITING

Granada, Spain
Hospital General Universitario Dr. Balmis de Alicante
RECRUITING

Alicante, Spain
Hospital General Universitario de Valencia
RECRUITING

Valencia, Spain
Hospital Universitario Cruces
RECRUITING

Barakaldo, Spain
Hospital Universitario Nuestra Señora de Candelaria
RECRUITING

Santa Cruz de Tenerife, Spain
Hospital Universitario Vall D'Hebron
RECRUITING

Barcelona, Spain
Hospital Universitario de Jerez de La Frontera
RECRUITING

Jerez de la Frontera, Spain
Hospital de La Santa Creu I Sant Pau
RECRUITING

Barcelona, Spain
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
RECRUITING

Meldola, Italy
Instituto Europeo di Oncologia (IEO)
RECRUITING

Milan, Italy
Kantonsspital Winterthur
RECRUITING

Winterthur, Switzerland
LMU München
RECRUITING

München, Germany
National University Hospital
RECRUITING

Singapore, Singapore
North Estonia Medical Centre Foundation
RECRUITING

Talinn, Estonia
Nuovo Ospedale di Prato Santo Stefano
RECRUITING

Prato, Italy
Pius Hospital, University Medicine Oldenburg
NOT_YET_RECRUITING

Oldenburg, Germany
Ruhrlandklinik Essen
RECRUITING

Essen, Germany
St James's Hospital
RECRUITING

Dublin, Ireland
St. Vincent's University Hospital
NOT_YET_RECRUITING

Dublin, Ireland
University Hospital Basel
RECRUITING

Basel, Switzerland
University of Perugia, AO SM Misericorida Perugia
NOT_YET_RECRUITING

Perugia, Italy
Wien AKH
NOT_YET_RECRUITING

Vienna, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.